Brand Name Manufacturer Previews New DTC Ad Campaign to Further Boost Sales of
High-Priced Blockbuster GLP-1 Drug Ozempic





 



BIG PHARMA EARNINGS WATCH: NOVO NORDISK

Brand Name Manufacturer Previews New DTC Ad Campaign to Further Boost Sales of
High-Priced Blockbuster GLP-1 Drug Ozempic



This week, pharmaceutical giant Novo Nordisk reported earnings that beat Wall
Street analysts’ expectations for the first quarter following price hikes on 12
of their prescription drugs so far this year.



During the Novo Nordisk earnings call
<[link removed]>
, an analyst from Bank of America posed a question about changes to expect on
the drug company’s Ozempic marketing strategy, to which Novo Nordisk’s
President and Executive Vice President of U.S. operations, Dave Moore,
responded the company’s commercial focus for the blockbuster GLP-1 will be to
double down on big spending on direct-to-consumer (DTC) advertising pushing
sales of the high-priced blockbuster, including through a new campaign titled
the “Ozempic Era.”



Novo Nordisk spent $208 million
<[link removed]>
on DTC advertising promoting Ozempic in 2023 alone.



Big Pharma’s staggering spending on advertising directly targeting consumers,
like Novo Nordisk’s marketing of Ozempic, often walks hand-in-hand with price
hikes on these blockbuster products, increases sales of high-priced drugs, and
costs U.S. taxpayers billions of dollars.



The Campaign for Sustainable Rx Pricing (CSRxP) released an analysis
<[link removed]>
earlier this year that found taxing or prohibiting DTC ads for the ten largest
pharmaceutical companies in the U.S. would result in increased federal tax
revenue between $1.5 and $1.7 billion per year. Read the full analysisHERE
<[link removed]>
.



Get the full rundown of Novo Nordisk’s Q1 earnings here:



Novo Nordisk

* Novo Nordisk beat Wall Street
<[link removed]>
analysts’ expectations for the first quarter.
* The Big Pharma giant company reported $11.9 billion
<[link removed]> in
revenue for Q1.
* The Big Pharma giant’s GLP-1 drug Wegovy brought in $2.6
<[link removed]>
million in sales during the first quarter.
* The company’s other GLP-1 product, weight loss drug Ozempic, brought in
$4.9 million
<[link removed]>
.
This strong earnings report from the Big Pharma giant demonstrates its
continued practice of hiking prices across its drug portfolio.



Novo Nordisk

* Since January 2025, Novo Nordisk has increased the cost of 12 prescription
drugs <[link removed]> at an average rate of 4.7
percent.
* Last year, Novo Nordisk hiked prices on 10 prescription drugs
<[link removed]>, including a 3.5 percent
increase on their blockbuster weight loss drug Ozempic.
* In 2023, Novo Nordisk hiked prices on 11 prescription drugs
<[link removed]>, including a 4.9 percent
increase on their GLP-1 drug Ozempic.
Read the full CSRxP DTC report HERE
<[link removed]>
.



Read more on Q1 earnings from Johnson & Johnson HERE
<[link removed]>.

Read more on Q1 earnings from AbbVie, Roche, Gilead, Merck and Bristol Myers
SquibbHERE
<[link removed]>
.



Read more on Q1 earnings from AstraZeneca and Novartis HERE
<[link removed]>.



Read more on Q1 earnings from Amgen and Eli Lilly HERE
<[link removed]>.



Learn more about solutions to lower prescription drug prices and hold Big
Pharma accountableHERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>